Summary A novel tumour system has been used to study the effect of natural killer cells on tumour growth by using agents which modify natural killer cell activity. The tumour cells are hybridoma cells which secrete antibody specific for red blood cells so that tumour growth can be quantitated by a haemolytic plaque assay. Spleen-seeking variants have been derived from original hybrids which are sensitive to natural killer cells. Treatment of mice with polyinosinic-polycytidylic acid substantially enhanced natural killer cell activity and correlated closely with a reduction in the growth of the hybridoma tumour cells in the spleen and life extension. Conversely, a single injection of anti-asialo GM1 antibody resulted in a substantial increase in the number of plaque forming splenic tumour cells and virtual elimination of natural killer cell activity. These data demonstrate the important role of natural killer cells in constraining the growth of a tumour of B cell origin and establishes the usefulness of this tumour model in studying the biology of effects on tumour growth.
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Natural killer (NK) cells have the ability to lyse certain tumour cells in vitro and are recognised as a potentially important anti-tumour effector mechanism in vivo. Several types of investigations have been carried out in order to understand the relationship of the host's non-adaptive immune system to the development of tumours and their metastatic spread. Adoptive transfer of purified rat large granular lymphocytes, cells closely associated with NK activity, has been shown to decrease the number of pulmonary metastases of MADBI06 adenocarcinoma cells (Barlozzari et al., 1985) in the rat and cultured NK cell clones when transferred back into mice can inhibit tumour metastasis and suppress the induction of radiation-induced thymic leukaemia (Warner & Dennert, 1982) . Further evidence for the role of NK cells in controlling the incidence of spontaneous or experimentally-induced neoplasia has been obtained by using agents with modulate NK activity in vivo. For example, agents 'vhich activate or augment NK activity, such as adjuvants (Hanna & Burton, 1981) or interferon (IFN) inducers (Hanna & Fidler, 1981) can decrease the number of metastases in experimental tumours and mice rendered selectively NK deficient by injection of anti-asialo GM1 antibody cannot regulate the growth of an NK susceptible lymphoma (Kawase et al., 1982 ). An interesting correlation has been found between susceptibility to NK cells and tumourigenicity. Several workers have now shown that depletion of NK activity in mice with anti-asialo GM1 antibody can influence the survival of tumour cells (Habu et al., 1981) and cause an increase in their metastatic spread (Gorelik et al., 1982) . In addition to these investigations other studies involving mice congenitally deficient in NK activity have focussed attention on the role of NK cells in controlling tumour growth. For example an increase in the number of B16 melanoma lung metastases in beige mice correlates with low levels of NK cell activity (Talmage et al., 1980) . In many of these investigations the quantitation of tumour growth relies on counting colonies on the surface of an organ or measuring the tumour diameter. We have recently described a murine tumour model system where the tumour cells are hybridomas derived from a myeloma cell fused with a normal B cell which secretes anti-red blood cell antibody (Ezaki & Marbrook, 1985) . Consequently tumour growth can be followed by measuring plaque forming cells in a given organ or the presence of antibody in the blood, in an extremely quantitative manner. In this present report we have used two spleen seeking variants, one of which secretes anti-bovine red blood cell (BRBC) antibody and the other anti-horse red blood cell (HRBC) antibody, in order to study the effect of splenic NK cells on the growth of B cell derived tumours by employing agents which modify NK cell activity.
Materials and methods

Mice
Male and female, (BALB/c x DBA/2) F1 H-2d (designated CDF1), CBA/J H-2k, DBA/2 H-2d and (CBA x DBA)F1 mice aged 9-12 weeks were obtained from the mouse colony in the School of Medicine University of Auckland. They were age and sex matched for each experiment.
Hybridoma cells Two hybridoma cell lines, one secreting monoclonal antibody (IgG) directed against BRBC (Abo-1) and the other secreting monoclonal antibody (IgM) directed against HRBC (HeC3) were isolated following the fusion of BALB/c antibody-forming cells and the myeloma NS-1 (H-2d) as described previously (Skinner & Marbrook, 1981) . The hybridomas were passaged several times in young BALB/c mice and two variant sublines were derived designated BSp and HeSp (Ezaki & Marbrook, 1985) . These two tumourigenic variants grew as spleen colonies in normal adult CDF1 and BALB/c mice, but would not grow in DBA/2, CBA/J or (CBAxDBA)F1 mice. Once isolated, a stock of the spleen-seeking variant cell lines was frozen. After 4-5 in vivo passages the cell line was discarded and fresh cells were taken from the frozen stock. In vivo passaged tumours were used for all in vivo experiments. BSp did not grow in vitro but HSp could also be maintained in culture.
Eighty to ninety percent of hybridoma cells were plaqueforming cells.
Cytotoxic assay for NK cells Fresh spleen cells were incubated with 5 x 103 51Cr-labelled YAC-1 or HeC3 cells for 4h at a range of killer to target ratios. After 4h the 51Cr released into the supernatant was counted in a gamma analyser and percent specific lysis was calculated as described previously (Ezaki et al., 1983) .
Plaque reduction assay for cytotoxicity The plaque reduction assay was carried out as previously described (Skinner & Marbrook, 1981; Ezaki et al., 1984 (Ezaki & Marbrook, 1985) . The cells grew exponentially in the spleen with a doubling time of 12 h. The HeSp line had similar growth characteristics but had a doubling time in vivo of -19 h. Consequently, a standard tumour cell inoculum (6 x 105 viable cells) was injected i.v. and the rate of tumour growth was assessed by the number of specific PFC in the spleen after 14 days (BSp) or 17 days (HeSp) as previously described, (Ezaki & Marbrook, 1985) .
Test for statistical significance The probability that the difference between two experimental groups was not due to chance variation was estimated by using the two sample t-test (Huntsberger & Leaverton, 1970 Poly I-C treatment decreases tumour growth As poly I-C is a potent inducer of IFN which in turn increases the NK activity of spleen cells (Gidlund et al., 1978 ) the effect of treating mice with poly I-C on tumour growth was determined. CDF1 mice received their first dose of poly I-C 24 h before tumour inoculation (6 x l05 HeSp) and then at 48h intervals for 12 days. Seventeen days after receiving tumour cells, individual mice were assayed for splenic NK activity by their ability to kill YAC-1 targets and for tumour growth by individual tumour PFC. There was a positive correlation between the NK activity in the spleen and a lack of tumour growth. Spleens from poly I-C treated mice which were high in NK activity, had less than 300 PFC tumour cells per spleen and two mice had no detectable tumour cells at the time of assay. Untreated mice which had low NK activity had at least 3 x 104 PFC tumour cells per spleen (Figure 2) .
The survival of mice after poly I-C treatment was also compared with that of untreated animals. The mean survival time of mice inoculated with HeSp was increased from 21 to 34 days after treatment. Likewise the survival time of mice inoculated with BSp was increased from 22 days in untreated mice to 34 days in poly I-C treated animals ( Figure 3 ). An additional effect with the BSp tumour was that treated mice became paraplegic 3-4 days prior to death and histological examination of the femur showed that the tumour had metastasised to the bone marrow in these mice (data not shown). Figure 4A clearly demonstrate that treatment with the antiserum decreases NK activity measured on HeC3 target cells. In Figure 4B the assay is the plaque reduction assay and although the antibody diminishes the ability of the spleen cells to cause a reduction in tumour PFC it is not as marked as the reduction measured by 51Cr release. Interestingly there is little difference in the cytotoxic activity of poly I-C treated spleen cells compared with untreated cells, except at high effector cell numbers, suggesting that other types of cytotoxic activity may be measured by the plaque reduction technique. A further group of mice which had been treated with antiasialo GM1 antiserum were injected with 6 x IO' HeSp tumour cells and after 17 days their spleens were assayed for growth of tumour cells by PFC. A marked difference was noted in the appearance of spleens which had been treated, compared with controls ( Figure 5 ). The spleens from treated animals were considerably larger and had many more Tumour growth in young mice As tumour lines were originally selected in young mice when NK activity is low (Herberman et al., 1975 ) the growth of the hybridoma variants was compared in young (3-4 week old) and mature (12 week old mice). There were 10 times more tumour cells in the young mice compared to adult mice at the time of assay and this correlated with a lower NK activity measured by the killing of both HeC3 and YAC-1 by Cr release (Table I) . (Hanna & Burton, 1981; Warner & Dennert, 1982; Barlozzari et al., 1985) . Although blood borne metastases are likely targets for NK cell activity, it is generally accepted that the overall 'level' of NK cells may not reflect the concentration in crucial sites for potential control of tumour growth (Moore, 1985) . With this in mind, the growth of tumour cells was followed at a site where the NK cell concentration is readily measured and can be modulated by extrinsic agents. The hybridoma tumour cell sublines grow predorninantly in the spleen and can be measured accurately as haemolytic plaque forming cells. Even though the spleen-seeking variants proliferate in an organ which is usually regarded as NK-rich, they may in fact proliferate within a particular permissive microenvironment of the spleen. The sensitivity of hybridoma cells to NK cytotoxicity has been studied in some detail, particularly in relation to the rate of killing and the competitive recognition of targets by NK cells (Ezaki et al., 1983) . All hybridomas tested, including the parent myeloma, NS-1, from which the hybridoma was derived, are sensitive to NK cells and selection of hybridomas after successive cycles of treatment with NK populations have not yielded NK resistant lines (unpublished results). In the in vitro analysis of HeC3, it is not lysed as readily as YAC-1 cells (Figure 1 ) but it is important to note that the hierarchy of NK activity in the spleens from different strains of mice is the same whether measured by YAC-1 or HeC3. When the advantages of using the plaque reduction assay were used, it should be noted that 80% reduction in PFC could be observed ( Figure 4B ).
We have adopted a protocol which can quite clearly increase or decrease NK activity in the target organs of the hybridoma and have used injections of the double stranded polynucleotide poly I-C and antibody directed against asialo GM1 to increase or decrease NK activity. Injection of poly I-C, a potent inducer of IFN, one day before tumour inoculation and continued on alternate days for 12 days, increased the survival time of mice carrying both spleenseeking variants and resulted in a marked decrease in tumour growth after 14-17 days (Figures 2 and 3) . The importance of IFN inducers in boosting NK activity is well established (Djeu et al., 1979) and high NK activity in poly I-C treated mice correlated with a reduction of tumour growth. However, the study of the effect of IFN-inducers raises the question of whether direct or indirect effects are being observed. There are direct effects of IFN on tumour growth (Gresser & Tovey, 1978) , and activated macrophages (Kleineman et al., 1983) or lymphokine-activated killer cells (Grimm et al., 1982) may also be involved. A single dose of poly I-C increases NK activity and enhancement only lasts for a short time. Repetitive treatments were required in this study, as increase in survival and decrease in tumour growth is related to the length of time of treatment with poly I-C (unpublished observations). If this form of treatment is to provide a means of immunotherapy for cancer patients then the adverse effects of repetitive injections, such as fever, reduced haemopoiesis, coagulation and autoimmune disease must be overcome. Recently a non-toxic mismatched analogue of poly I-C has been successful in enhancing NK activity and reducing P77 tumour lung surface colonies in rats (Nolibe et al., 1985) and may prove to be a useful immunotherapeutic agent.
Natural killer cells can be depleted in mice and rats by injecting the animals with anti-asialo GM1 antibody and although some T lymphocytes are positive for asialo GM, such treatment has virtually no effect on T cell responses (Gorelik et al., 1982; & unpublished observations) . Our data clearly demonstrate that anti-asialo GM, antibody treatment reduces the number of cytotoxic cells in both a normal spleen and the spleen of poly I-C treated animals (Figure 4) . It is of interest that, at very high effector to target ratios, there was actually an inhibition of killing ( Figure 4B ). This phenomenon has been observed with 51Cr release assays (unpublished observations) but is particularly marked in the sensitive PR assay at effector to target ratios of 3000 to I and long incubation times. These data emphasize the problems of measuring the action of cytotoxic cells which are present at very low frequencies. Currently, it cannot be deduced whether the apparent inhibition of killing is attributable to non-optimal conditions for cytotoxic cell activity or whether there are cells which suppress the normal cytotoxic activity of NK cells.
Tumour growth in mice after treatment with anti-asialo GM, antiserum was substantially reduced but whether this effect is due to a defined subset of NK cells remains to be elucidated. As more antibodies become available which react with different subsets of NK cells it should be possible to determine the subset(s) which may be involved in the control of tumour growth and metastases. Newborn mice have low levels of NK activity and it is still low in the spleen at 3-4 weeks coMnpared to adult 12 week old mice (Table I) . Increased tumour growth correlates with this low activity in young mice although other mechanisms of immune constraints are also immature at this age. It has to be borne in mind that measurement of NK cells depends on the concentration of cytotoxic cells. The growth of tumour cells in the spleen will reduce the concentration of NK cells in suspension and could also act as cold target inhibitors in cytotoxicity assays. The influence of these factors on assays for NK cell activity has been studied previously (Ezaki et al., 1983) and do not influence the conclusion of this work.
In summary the present study in which the corrlelation between NK cell levels and the rate of tumour growth at the same site has been followed provides further evidence that NK cells may play an important role in the control of tumour growth and demonstrates the potential use of this novel tumour system for studying methods of immunotherapy which may be useful in the treatment of cancer. 
